International journal of dermatology · 2023
JAK inhibitors: a novel, safe, and efficacious therapy for pyoderma gangrenosum.
Клинический случайСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Castro Luiz G M
Аннотация
BACKGROUND: Pyoderma gangrenosum currently lacks standardized therapy. New safer and more efficacious therapies are welcome.
AIMS: To present two new PG cases treated with JAK inhibitors, adding to the small existing experience METHODS & METHODS: Two case reports of PG patients successfully treated with tofacitinib and baricitinib.
RESULTS: Both patients were cured and presented no relapse. Patient # 1 used baricitinib 2 mg bid for 39 days while patient # 2 was treated with tofacitinib 5 mg bid for 120 days. No adverse reactions were seen.
DISCUSSION: The increasing usage of JAKi to treat inflammatory diseases had a positive reflex on PG therapy. Fifteen PG cases treated with these drugs had been found in literature and the two new cases here described add to the limited existing experience.
CONCLUSION: This is a novel use of tofacitinib and baricitinib beyond the approved indications. JAKi are a welcome addition to our options to manage patients with PG.
AIMS: To present two new PG cases treated with JAK inhibitors, adding to the small existing experience METHODS & METHODS: Two case reports of PG patients successfully treated with tofacitinib and baricitinib.
RESULTS: Both patients were cured and presented no relapse. Patient # 1 used baricitinib 2 mg bid for 39 days while patient # 2 was treated with tofacitinib 5 mg bid for 120 days. No adverse reactions were seen.
DISCUSSION: The increasing usage of JAKi to treat inflammatory diseases had a positive reflex on PG therapy. Fifteen PG cases treated with these drugs had been found in literature and the two new cases here described add to the limited existing experience.
CONCLUSION: This is a novel use of tofacitinib and baricitinib beyond the approved indications. JAKi are a welcome addition to our options to manage patients with PG.